Fig. 4.

Exploratory measures of efficacy during the last 3 months of the double‐blind treatment phase (DBTP; months 4 through 6) in subgroups achieving ≥50%, ≥75%, and 100% response. (A) Mean change in monthly migraine days (MMD) from baseline. (B) Mean change in acute migraine‐specific medication treatment days (MSMD) from baseline. (C) Mean change in 6‐item Headache Impact Test (HIT‐6) from baseline. (D) Mean change in Modified Migraine Disability Assessment (mMIDAS) total score from baseline (every 3 months [Q3M]). The mMIDAS was converted into a Q3M assessment of disability. The mMIDAS scores were summed for months 4, 5, and 6 by taking the average of these post‐baseline assessments and multiplying by 3 (if at least 1 mMIDAS was present).